

SEP. 14 2007

PTO/SB/08A (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/783,927
Filing Date	February 20, 2004
First Named Inventor	Ronald A. Fleming
Art Unit	1614
Examiner Name	James D. Anderson
Attorney Docket Number	Kucera-5001

Sheet 1 of 8

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US- 3,798,209-A	03-19-1974	Witkowski et al.	
	A2	US- RE29,835-Re	11-14-1978	Witkowski et al.	
	A3	US- 4,211,771-A	07-08-1980	Witkowski et al.	
	A4	US- 4,444,766-A	04-24-1984	Bosies et al.	
	A5	US- 4,493,832-A	01-15-1985	Teraji et al.	
	A6	US- 4,522,811-A	06-11-1985	Eppstein et al.	
	A7	US- 4,559,157-A	12-17-1985	Smith et al.	
	A8	US- 4,562,179-A	12-31-1985	Teraji et al.	
	A9	US- 4,599,205-A	07-08-1986	Lautenschlager et al.	
	A10	US- 4,608,392-A	08-26-1986	Jacquet et al.	
	A11	US- 4,820,508-A	04-11-1989	Wortzman	
	A12	US- 4,938,949-A	07-03-1990	Borch et al.	
	A13	US- 4,992,478-A	02-12-1991	Geria	
	A14	US- 5,026,687-A	06-25-1991	Yarchoan et al.	
	A15	US- 5,116,992-A	05-26-1992	Braquet et al.	
	A16	US- 5,496,546-A	03-05-1996	Wang et al.	
	A17	US- 5,614,548-A	03-25-1997	Piantadosi et al.	
	A18	US- 5,633,388-A	03-27-1997	Diana et al.	
	A19	US- 5,770,584-A	06-23-1998	Kucera et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	2	of	8
-------	---	----	---

Application Number	10/783,927
Filing Date	February 20, 2004
First Named Inventor	Fleming et al.
Art Unit	1614
Examiner Name	James D. Anderson
Attorney Docket Number	Kucera-5001

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 <sup>2</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	B1	DE 19914474	10-07-1999	Hoffmann-La Roche	abstract	
	B2	JP 08-268890	10-15-1996	Eisai Co. Lt.d	abstract	
	B3	JP 10-101591	04-21-1998	Eisai Co. Ltd.	abstract	
	B4	WO 90/11079	10-04-1990	Alcon Laboratories		
	B5	WO 91/05558	05-02-1991	Boehringer-Mannheim	abstract	
	B6	WO 91/09602	07-11-1991	Boehrigner-Mannheim	abstract	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/783,927
Filing Date	February 20, 2004
First Named Inventor	Ronald A. Fleming
Art Unit	1614
Examiner Name	James D. Anderson
Attorney Docket Number	Kucera-5001

Sheet	4	of	8
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Application Number</b>		10/783,927
				<b>Filing Date</b>		February 20, 2004
				<b>First Named Inventor</b>		Ronald A. Fleming
				<b>Art Unit</b>		1614
				<b>Examiner Name</b>		James D. Anderson
<b>Sheet</b>	5	<b>of</b>	8	<b>Attorney Docket Number</b>		Kucera-5001

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	ALT, M., et al.: "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," Hepatology, 22:707-717, 1995	
	C2	ALT, M., et al.: "Core specific antisense phosphorothioate oligodeoxynucleotides . . .," Archives of Virology, 142:589-599, 1997	
	C3	ATTWOOD, et al.: "The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase," Antiviral Chemistry and "Chemotherapy, 10(5):259-273, 1999	
	C4	BATTAGLIA, A.M., et al.: "Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection", Ann. Pharmacother, 34:487-494, 2000	
	C5	BERENGUER, M., et al.: "Hepatitis C virus in the transplant setting" Antivir. Ther., 3(supp. 3): 125-136, 1998	
	C6	BUCHEN-OSMOND, C., Togaviridae. In: ICTVdB - The Universal Virus Database, version 3. ICTVdB Management, www.ictvdb.rothamsted.ack.uk/ICTVdB/00.073.01.001.htm.	
	C7	CENTERS FOR DISEASE CONTROL AND PREVENTION: "Update: Severe Acute Respiratory Syndrome-Worldwide . . ." Morbidity and Mortality Weekly Report, 52(28): 664-665, 2003	
	C8	CHU, M., et al.: "Structure of Sch 68631: A new hepatitis C proteinase inhibitor from Streptomyces sp.," Tetrahedron Letters, 37:7229-7232, 1996	
	C9	CINATL, J., et al.: "Treatment of SARS with human interferons," Lancet, 362(9380):293-294, 2003	
	C10	DAVIS, G.L.: " Current therapy for chronic Hepatitis C," Gastroenterolgy 118:S104-S114, 2000	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	6	of	8	Application Number	10/783,927
				Filing Date	February 20, 2004
				First Named Inventor	Ronald A. Fleming
				Art Unit	1614
				Examiner Name	James D. Anderson
				Attorney Docket Number	Kucera-5001

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C11	FERRARI E., et al.: "Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli," Journal of Virology, 73(2), 1649-1654, 1999	
	C12	GALDERISI, U., et al.: "Antisense oligonucleotides as therapeutic agents, ", Journal of Cellular Physiology, 181(2):251-257, 1999	
	C13	HOLMES, K.V.: "SARS-associated coronavirus", New England Journal of Medicine, 348 (20):1948-1951, 2003	
	C14	HSU, LY., et al.: "Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts," Emerg. Infect. Dis., 9(6):713-717, 2003	
	C15	KAKIUCHI, N., et al.: "Non-peptide inhibitors of HCV serine proteinase,": FEBS Letters, 421 (3):217-220, 1998	
	C16	KRUGNER-HIGBY, L., et al.: "Membrane-interactive phospholipids inhibit HIV type 1-induced cell . . .," AIDS Res. & Human Retrovir., 11(6):705-712, 1995	
	C17	KUCERA, L.S., et al.: "Synthesis and Evaluation of a Novel Synthetic Phosphocholine Lipid-AZT . . .," Nucleosides, Nucleotides, and Nucleic Acids, 23(1-2):385-399, 2004	
	C18	LOHMANN, V., et al.: "Biochemical and kinetic analyses for NS5B RNA-dependent RNA polymerase of the hepatitis C Virus," Virology, 249(1):108-118, 1998	
	C19	MACEJAK, D.J., et al.: "Inhibition of viral replication by nuclease resistant hammerhead ribozymes directed . . .," Hepatology, 30(4 Pt 2):409A, abstract 995, 1999	
	C20	MARRA, M.A., et al.: "The Genome sequence of the SARS-associated coronavirus," Science, vol. 300 (5624):1399-1404, 2003	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	7	of	8	Application Number	10/783,927
				Filing Date	February 20, 2004
				First Named Inventor	Ronald A. Fleming
				Art Unit	1614
				Examiner Name	James D. Anderson
				Attorney Docket Number	Kucera-5001

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C21	MEYER, K.L., et al.: "In vitro evaluation of phosphocholine and quaternary ammonium containing lipid . . .," Journal of Medicinal Chemistry, 34(4):1377-1383, 1991	
	C22	MORRIS-NATSCHKE, S., et al.: "Synthesis of sulfur analogues of alkyl lysophospholipid and neoplastic cell growth inhibitory properties," J. Med. Chem., 29(10):2114-2117, 1986	
	C23	OUYANG, H., et al.: "Structure-activity relationship for enhancement of paracellular permeability . . .," J. Med. Chem., 45(13):2857-2866, 2002	
	C24	PIANTADIOSI, C., et al.: "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anit-HIV-1 activity," J. Med. Chem., 34(4):1408-1414, 1991	
	C25	POUTANEN, S.M., et al.: "Identification of severe acute respiratory syndrome in Canada," N. Engl. J. Med., 348(20):1995-2005, 2003	
	C26	QASIM, M.A., et al.: "Intescaffolding additivity. Association of P1 variants of eglin c and of turkey ovomucoid third domain . . .," Biochemistry, 36(7):1598-1607, 1997	
	C27	RAINER, T.H., et al.: "Evaluation WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital," Brit. Med. J., 326(7403):1354-1358, 2003	
	C28	ROTA, P.A., et al.: "Characterization of a novel coronavirus associated with severe acute respiratory syndrome," Science, 300(5624):1394-1399, 2003	
	C29	SUDO, K., et al.: "Novel hepatitis C virus protease inhibitors: thiazolidine derivatives," Biochemical and Biophysical Research Communications, 238:643-647, 1997	
	C30	SUDO, K., et al.: "Erratum: Novel hepatitis C virus protease inhibitors: 2,4,6-trihydroxy,3-nitro-benzamide . . .," Antiviral Chemistry and Chemotherapy, 8(6),186, 1998	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	8	of	8	Application Number	10/783,927
				Filing Date	February 20, 2004
				First Named Inventor	Ronald A. Fleming
				Art Unit	1614
				Examiner Name	James D. Anderson
				Attorney Docket Number	Kucera-5001

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C31	SUDO, K., et al.: "Establishment of an in vitro assay sytem for screening hepatitis C virus protease inhibitors . . .," Antiviral Research, 32(1):9-18, 1996	
	C32	TAKESHITA, N., et al.: "An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C . . .," Analytical Biochemistry, 247(2):242-246, 1997	
	C33	TSANG, K.W., et al., "A cluster of cases of severe acute respiratory syndrome in Hong Kong," N. Engl. J. Med., 348(20):1977-1985, 2003	
	C34	CHU, M., et al.: "Isolation and structure of SCH 351633: a novel hepatitis . . .," Bioorganic and Medicinal Chemistry Letters, 9(14): 1949-1952, 1999	
	C35	KUCERA, L.S., et al.: "Novel membrane-interactive ether lipid analogs that inhibit infections HIV-1 production . . .," Aids Res. Hum. Retrovirus, 6:491-501, 1990	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.